Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/12/2017 01/13/2017 01/17/2017 01/18/2017 01/19/2017 Date
20.8(c) 21.4(c) 20.5(c) 21.1(c) 20.7(c) Last
431 448 470 935 480 333 572 459 462 329 Volume
+0.24% +2.88% -4.21% +2.93% -1.90% Change
More quotes
Financials ($)
Sales 2016 517 M
EBIT 2016 35,8 M
Net income 2016 -44,8 M
Finance 2016 78,5 M
Yield 2016 -
Sales 2017 552 M
EBIT 2017 5,41 M
Net income 2017 -35,3 M
Debt 2017 7,06 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 1,73x
EV / Sales2017 1,78x
Capitalization 973 M
More Financials
Company
Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders.The company's two main products are Ampyra and Zanaflex Capsules.The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short... 
More about the company
Surperformance© ratings of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACORDA THERAPEUTICS INC
01/19 ACORDA THERAPEUTICS : Investigators from Acorda Therapeutics Release New Data on..
01/09 ACORDA THERAPEUTICS, INC. (NASDAQ : ACOR) Files An 8-K Results of Operations and..
01/09 ACORDA THERAPEUTICS INC : Results of Operations and Financial Condition, Financi..
01/09 ACORDA THERAPEUTICS : Announces 2016 AMPYRA Net Sales and 2017 Financial Guidanc..
01/06 ACORDA THERAPEUTICS : to Present at the 35th Annual J.P. Morgan Healthcare Confe..
2016 ACORDA THERAPEUTICS : to Present at the 35th Annual J.P. Morgan Healthcare Confe..
2016 ACORDA THERAPEUTICS : Patent Issued for Compositions and Methods for Treatment d..
2016 ACORDA THERAPEUTICS : to Discontinue Development of Dalfampridine for Treatment ..
2016 ACORDA THERAPEUTICS : Assigned Patent
2016 ACORDA THERAPEUTICS : to Present at the 28th Annual Piper Jaffray Healthcare Con..
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
Latest Tweets
01/17Want the latest upgrades & downgrades for $GLW $ACOR $MITL $PJC $IART? Ch.. 
01/13? FRIDAY'S UNUSUAL CALL FLOW:
4
01/13$ACOR .. FEB 27 CALL Activity 1500 block @$1.60 by OFFER .. Expire Feb 17 
01/13$ACOR Feb 27 Call Buyer +1500 for $1.60 
01/10Acorda Therapeutics (ACOR) presents at 35th Annual J.P. Morgan Healthcare Con.. 
More tweets
Qtime:62
News from SeekingAlpha
01/10 Acorda Therapeutics (ACOR) presents at 35th Annual J.P. Morgan Healthcare Con..
01/09 Acorda announces 2016 AMPYRA net sales and 2017 financial guidance
01/03 Drug price hikes continue; IBB +1.4% today
2016 Today's healthcare analyst action
2016 Acorda nixes development of dalfampridine for PSWD after failed late-stage st..
Advertisement
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Full-screen chart
Technical analysis trends ACORDA THERAPEUTI...
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 32,0 $
Spread / Average Target 52%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ronald Cohen President, Chief Executive Officer & Director
David Lawrence Chief Financial & Accounting Officer
Andrew R. Blight Chief Scientific Officer
Anthony O. Caggiano Vice President-Research & Development
Richard P. Batycky Chief Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACORDA THERAPEUTICS IN..10.11%973
AMGEN, INC.5.19%115 881
GILEAD SCIENCES, INC.-0.06%95 028
CELGENE CORPORATION-1.84%89 319
REGENERON PHARMACEUTIC..-1.00%38 280
ACTELION LTD4.58%24 476
More Results